Masataka Murakami

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 10 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masataka Murakami. Retrieved from https://idiyas.com/inventor/masataka-murakami

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 95.0

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 11.7

ph-index = 5

Forward Citations = 67(Granted Patents)

Location History:

Osaka, JP (2014)
Kanagawa, JP (2018 - 2022)
Fujisawa, JP (2020 - 2023)

Company Filing History:

20 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2026

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12723028 - Heterocyclic compound (2026-09-01),

2. 12637418 - Heterocyclic compounds as antagonist of NMDA (2026-05-26),

3. 12630509 - Heterocyclic NMDA antagonists (2026-05-19),

4. 12528802 - Heterocyclic compound (2026-01-20),

5. 12378256 - Heterocyclic compound (2025-08-05),

6. 11834409 - Heterocyclic NMDA antagonists (2023-12-05),

7. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

8. 11459325 - Heterocyclic compound (2022-10-04),

9. 11274101 - Heterocyclic compound (2022-03-15),

10. 11236099 - Heterocyclic compound (2022-02-01),

11. 10899752 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2021-01-26),

12. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

13. 10610520 - Heterocyclic compound (2020-04-07),

14. 10548899 - Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity (2020-02-04),

15. 10428056 - Heterocyclic compound (2019-10-01),

Sure, here is the article about inventor Masataka Murakami:

Title: Inventor Spotlight: Masataka Murakami

Introduction:

Masataka Murakami, a prolific inventor hailing from Kanagawa, Japan, has made significant contributions in the field of pharmacology with his groundbreaking patents.

Latest Patents:

His recent patents include innovations such as "Heterocyclic NMDA Antagonists," a compound specifically designed to act as an antagonistic agent against the NMDA receptor, which shows promise in treating conditions like depression, bipolar disorder, and migraines. Another notable invention is the "Heterocyclic Compound and Use Thereof," aimed at prophylaxis or treatment of major depression, bipolar disorder, and other related conditions.

Career Highlights:

With an impressive portfolio of 15 patents to his name, Masataka Murakami has demonstrated a keen understanding of pharmaceutical research and development. He is currently associated with Takeda Pharmaceutical Company Limited, a renowned player in the healthcare industry known for its innovative solutions.

Collaborations:

Murakami has had the privilege of collaborating with esteemed colleagues such as Minoru Nakamura and Makoto Kamata, further enriching the realm of pharmaceutical advancements with their collective expertise.

Conclusion:

In conclusion, Masataka Murakami stands out as a distinguished inventor whose work has the potential to revolutionize the treatment of various psychological and neurological disorders. His innovative spirit and commitment to advancing pharmacological solutions make him a valuable asset in the field of medical science.

If you require more information on Masataka Murakami or any other inventors, feel free to explore our website idiyas.com for further insights and updates on pioneers in the world of innovations and patents.

Profile summary based on public USPTO records.